A nasal spray that forms a barrier against COVID-19 is due to be launched locally next week, providing a secondary layer of protection, particularly in crowded, enclosed and high-risk settings. Touted as an additional, clinically-proven tool in the battle against the coronavirus, the Israeli product, Taffix™ (Powder) Spray Device, claims to offer 97 per cent shielding from respiratory viruses in the nasal cavity – also blocking SARS-CoV-2. Every application works within 50 seconds and gives five-hour protection, the manufacturer, Nasus Pharma said. It insists, however, that intra-nasal an...